Categories: CancerNewsVaccine

Keystone Symposia to Convene Global Leaders in Vaccinology Amidst Rising Public Health Concerns

WASHINGTON, April 15, 2025 /PRNewswire/ — June 4-7, 2025 – Keystone Symposia will host a timely meeting, “Vaccinology: Horizons Across Disease, Demography and Technology,” in Washington, D.C., bringing together industry, academic, and non-profit leaders from around the world to address pressing challenges in vaccine development and global health. The urgency of this meeting is underscored by recent events, such as the ongoing measles outbreaks in the U.S., which highlight the critical need for continued advancements in vaccinology and public health advocacy.

The conference will feature a provocative keynote address by Dr. Peter Hotez, titled “Vaccines and Immunizations in a Time of Global Boiling, Megacities, and Antiscience,” addressing the growing challenges to vaccine acceptance and the importance of scientific communication in combating misinformation.

Vaccine experts including meeting organizers and conference speakers Rino Rappuoli (Harvard University), Kanta Subbarao (Université Laval), Laurence Zitvogel (Institut Gustave Roussy) and Firdausi Qadri (International Centre for Diarrhoeal Disease Research) will convene to discuss strategies to overcome obstacles in the field and advance novel vaccine technologies.

The meeting will span the technology and biology of vaccine design against infectious diseases and cancer, to multidisciplinary global approaches to improve vaccine development, production and distribution, as presented by the World Health Organization and other global leaders.

Conference Highlights:

  • Session to include:
    • Learning the Molecular Immunology of mRNA Vaccines
    • Vaccines, Emerging Reality in Cancer Therapy
    • Preparing for New Pandemics and Emerging Infections
    • Understanding Mechanistic Immunology to Drive Vaccine Design
    • Designing and Evaluating New Vaccines
    • Exploiting Tissue Specific Protection to Prevention and Cure
  • Career Roundtable networking opportunity for Early-Career Scientists
  • Panel Discussion: Transforming Early-Stage Vaccine Development, moderated by Rino Rappuoli, with panelists John Tsang, Neil P King, and Firdausi Qadri
  • Endocrine Society booth offering expert guidance on impactful public policy advocacy for conference attendees

Leaders in the field are encouraged to attend this important meeting to leverage the opportunity for advancements, ideas, and collaborations. Learn more: https://www.keystonesymposia.org/conferences/conference-listing/meeting/g12025 

  • Early registration discounts are available until April 16th.
  • Poster abstracts are due by May 14th.
  • For those unable to attend in person, On Demand access to meeting content will be available for up to six months following the event.

Dr. Peter Hotez & Meeting Organizers Available for Interviews

Dr. Peter Hotez, a prominent voice in the field of vaccinology and a leading advocate for public health, is available for interviews to discuss the critical issues being addressed at the conference, including the importance of vaccination in preventing outbreaks of preventable diseases. Meeting organizers Rino Rappuoli, Kanta Subbarao, Laurence Zitvogel, and Firdausi Qadri are also available to provide expert commentary.

Media Assets

Media Contact:

Janice Miller, janicem@keystonesymposia.org
Marketing Director, Keystone Symposia

View original content to download multimedia:https://www.prnewswire.com/news-releases/keystone-symposia-to-convene-global-leaders-in-vaccinology-amidst-rising-public-health-concerns-302428842.html

SOURCE Keystone Symposia

Staff

Recent Posts

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

11 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

11 hours ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

11 hours ago